Main Organiser

Julius Centre University of Malaya

Co-organiser

Department of Social and Preventive Medicine, Faculty of Medicine, University of Malay

Supported by

University of Malaya

SURVIVAL OF HIGH GRADE GLIOMA PATIENTS RECEIVING CARMUSTINE WAFERS COMBINED TEMOZOLOMIDE

Author

Lee MC, Su HC, Wang HY

Institution

Department of Pharmacy, Chi-Mei Medical Center, Tainan, Taiwan

Abstract

Objectives: High-grade brain tumors, and particularly glioblastomas, are among the most aggressive tumors. Standard treatment for high grade glioma usually entails surgery followed by radiotherapy plus or minus temozolomide. Implanting carmustine wafers into the resection cavity represents which provide local delivery of the chemotherapeutic has consistently been reported to extend median survival by 2.5 months recently. The aim of this trial was to evaluate the effect of combined carmustine wafers and temozolomide.

Methods: The following databases were searched: Medline; Pubmed and Cochrane databases. Interventions included carmustine wafers combined temozolomide to patients with high- grade brain tumors. The search strategy identified 32 potentially relevant references which were screened online. We included 2 references.

Results: Overall survival rate at 12 months was no significant difference between implantation of carmustine wafers received radiotherapy with concomitant temozolomide and without (OR: 1.17[ 0.52, 2.64 ]).

Conclusion: In patients with high-grade gliomas, adding carmustine wafers with concomitant temozolomide did not improve survival. Whether concomitant temozolomide therapy in addition to carmustine wafers wafer implantation can improve overall survival, still more research to provide.